Betaliq
- Biotech or pharma, therapeutic R&D
Betaliq’s mission is to build a leading ophthalmic company with a robust pipeline, multiple strategic partnerships, and an efficient commercialization model to enhance accessibility of general ophthalmology products.
At the core of our strategy is an “Eye-Commerce platform”: a unique, one-stop solution that leverages a patient-pay, direct-fulfillment model to overcome the common access challenges in the U.S. ophthalmology market.
Our diverse range of products is sourced from both our internal pipeline and a network of established and emerging partnerships allowing us to serve a broad spectrum of medical needs in general ophthalmology.
To accelerate growth, we are exploring strategic initiatives to go public, including a Letter of Intent (LOI) for a reverse merger with Eyenovia, Inc. This will combine our FDA-approved micro-dosing technologies—EyeSol™ and Optejet™—into a new, publicly listed entity (NewCo) to expand market presence and innovation.
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}